Robert Wake

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.

Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.

Adrenal trauma: Elvis Presley Memorial Trauma Center experience.

Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.

Tubeless percutaneous nephrolithotomy for complex renal stone disease: single center experience.

Nonoperative management of blunt renal trauma: is routine early follow-up imaging necessary?

Contemporary analysis of erectile, voiding, and oncologic outcomes following primary targeted cryoablation of the prostate for clinically localized prostate cancer.

Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.

Single center comparison of laparoscopic cryoablation and CT-guided percutaneous cryoablation for renal tumors.

Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy.

Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues.

Variation in the incidence of and risk factors for the development of nephrolithiasis after radical or partial nephrectomy.

Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.

Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation.

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Rising Serum Uric Acid Level Is Negatively Associated with Survival in Renal Cell Carcinoma.